SCHEMBL3987812

SCHEMBL3987812

Cc1ccc(S(=O)(=O)OCCC2CN(Cc3ccc(C(F)(F)F)cc3)C(=O)N2C)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ MAPT P10636 3/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ PTGS2 P35354 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.40
▸ BCHE P06276 1/20 0.40
▸ ACHE P22303 1/20 0.40
▸ GAA P10253 2/20 0.38
▸ MCOLN3 Q8TDD5 1/20 0.37
▸ CRHBP P24387 1/20 0.37
▸ CRHR2 Q13324 1/20 0.37
▸ HSP90AA1 P07900 1/20 0.37
▸ CASP3 P42574 2/20 0.36
▸ CASP7 P55210 2/20 0.36
▸ PPARG P37231 2/20 0.36
▸ PPARD Q03181 2/20 0.36
▸ PPARA Q07869 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3990845 0.86 KCNA5 (0.42) LMNASMN1; SMN2MAPTMEN1KMT2A
SCHEMBL3988359 0.86 LMNA (0.43) LMNASMN1; SMN2MAPTALDH1A1BCHE
SCHEMBL13792676 0.86 LMNA (0.43) LMNASMN1; SMN2MAPTALDH1A1BCHE
SCHEMBL3996224 0.80 DRD2 (0.37) LMNASMN1; SMN2ALDH1A1GAAMCOLN3
SCHEMBL13792043 0.78 SIRT2 (0.41) LMNAALDH1A1PPARGPPARDPPARA
SCHEMBL13792417 0.77 CASP3 (0.40) MEN1KMT2AALDH1A1MCOLN3CASP3
SCHEMBL13792988 0.76 SIRT2 (0.40) LMNASMN1; SMN2MAPTALDH1A1
SCHEMBL13792902 0.75 PPARA (0.44) PPARGPPARDPPARA
SCHEMBL3994784 0.75 PPARA (0.44) PPARGPPARDPPARA
SCHEMBL6311561 0.73 BCHE (0.55) LMNASMN1; SMN2MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544812-B2 For example, 2-(4-{2-[1-(4-tert-Butyl-benzyl)-3-methyl-2-oxo-imidazolidin-4-yl]-ethoxy}-2-methyl-phenoxy)-2-methyl-propionic acid, 2-(4-{3-[1-(4-tert-Butyl-benzyl)-3-methyl-2-oxo-imidazolidin-4-yl]-propyl}-2-methyl-phenoky)-2-methyl-propionic acid; for treating diabetes mellitus ELI LILLY AND COMPANY (US) 2009-06-09 — — US disclosed
CN-1582279-A Peroxisome-activated receptor agonists LILLY CO ELI (US) 2005-02-16 — — CN disclosed
US-20050020652-A1 Peroxisome proliferator activated receptor agonists ELI LILLY AND COMPANY 2005-01-27 — — US disclosed
EP-1453811-A2 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2004-09-08 — — EP disclosed
WO-2003048130-A2 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2003-06-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020652-A1 Peroxisome proliferator activated receptor agonists PPARA, PPARD, PPARG LMNA 2723/4885SMN1; SMN2 4678/4885MAPT 4870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback